Korean J Intern Med.
2010 Dec;25(4):372-376. 10.3904/kjim.2010.25.4.372.
Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
- Affiliations
-
- 1Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
- 2Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. gie001@cnuh.co.kr
- 3Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
- 4Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
- 5Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
- 6Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
- KMID: 964717
- DOI: http://doi.org/10.3904/kjim.2010.25.4.372
Abstract
- BACKGROUND/AIMS
Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naive patients with CHB living in Daejeon and Chungcheong Province, South Korea.
METHODS
One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months.
RESULTS
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 +/- 188 IU/L, 150 +/- 138 IU/L, and 7.1 +/- 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough.
CONCLUSIONS
Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment Efficacy of Clevudine, Entecavir and Lamivudine in Treatment-naive Patients with HBeAg-Positive Chronic Hepatitis B
- Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B
- Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B
- Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B
- Development of Clevudine Resistance after Switching from Lamivudine in a Patient with Chronic Hepatitis B
